Botanix Pharmaceuticals Limited engages in the research and development of dermatology and antimicrobial products in Australia and the United States. Its product pipeline includes Sofpironium Bromide, a drug in development for the treatment of primary axillary hyperhidrosis that has completed Phase 3 clinical programs; BTX 1503, a transdermal gel formulation for the treatment of serious acne in adults and teenagers that has completed Phase II clinical trials; BTX 1801, which has completed Phase IIa clinical trials for the treatment of staphylococcus aureus and methicillin resistant staphylococcus aureus; BTX 1702 that is in Phase II clinical trials for the treatment of papulopustular rosacea; and BTX 1204A for the treatment of atopic dermatitis. Botanix Pharmaceuticals Limited was incorporated in 1984 and is based in West Perth, Australia.
Metrics to compare | BOT | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipBOTPeersSector | |
---|---|---|---|---|
P/E Ratio | −48.4x | −3.3x | −0.6x | |
PEG Ratio | 2.94 | 0.00 | 0.00 | |
Price/Book | 6.2x | 2.0x | 2.6x | |
Price / LTM Sales | 324.3x | 5.1x | 3.2x | |
Upside (Analyst Target) | 75.7% | 66.2% | 46.5% | |
Fair Value Upside | Unlock | 24.0% | 6.6% | Unlock |